Angiotensin II and its receptor in activated microglia enhanced neuronal loss and cognitive impairment following pilocarpine-induced status epilepticus

Molecular and Cellular Neuroscience

Volumn 65, Issue , 2015, Pages 58-67

  Sun, Hong ^a   Wu, HaiQin ^a   Yu, Xin ^b   Zhang, GuiLian ^a   Zhang, Ru ^a   Zhan, ShuQin ^a   Wang, HuQing ^a   Bu, Ning ^a   Ma, XiaoLing ^a   Li, YongNan ^c  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b 401 Hospital of PLA   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

AII; Cognitive impairment; Epilepsy; Losartan; Microglia; Neuronal loss

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; LOSARTAN; PILOCARPINE; TUMOR NECROSIS FACTOR ALPHA; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; EPILEPTIC STATE; HIPPOCAMPUS; MALE; MICROGLIA; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; COGNITION DISORDERS; COMPLICATION; DRUG EFFECTS; METABOLISM; NERVE CELL; PATHOLOGY; SPRAGUE DAWLEY RAT;

RATTUS;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; COGNITION DISORDERS; HIPPOCAMPUS; LOSARTAN; MALE; MICROGLIA; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 2; STATUS EPILEPTICUS;

EID: 84923537454     PISSN: 10447431     EISSN: 10959327     Source Type: Journal    
DOI: 10.1016/j.mcn.2015.02.014     Document Type: Article

References (49)

1. Abraham J., Fox P.D., Condello C., Bartolini A., Koh S. Minocycline attenuates microglia activation and blocks the long-term epileptogenic effects of early-life seizures. Neurobiol. Dis. 2012, 46:425-430.
2. Arif H., Buchsbaum R., Weintraub D., Pierro J., Resor S.R., Hirsch L.J. Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behav. 2009, 14:202-209.
3. Avanzini G., Depaulis A., Tassinari A., De Curtis M. Do seizures and epileptic activity worsen epilepsy and deteriorate cognitive function?. Epilepsia 2013, 543.
4. Bandopadhyay R., Liu J.Y., Sisodiya S.M., Thom M. A comparative study of the dentate gyrus in hippocampal sclerosis in epilepsy and dementia. Neuropathol. Appl. Neurobiol. 2014, 40:177-190.
5. Becker A., Grecksch G., Thiemann W., Hoellt V. Pentylentetrazol-kindling modulates stimulated dopamine release in the nucleus accumbens. Pharmacol. Biochem. Behav. 2000, 66:425-428.
6. Bild W., Hritcu L., Stefanescu C., Ciobica A. Inhibition of central angiotensin II enhances memory function and reduces oxidative stress status in rat hippocampus. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 43:79-88.
7. Chen J., Zhao Y., Chen S., Wang J., Xiao X., Ma X., Penchikala M., Xia H., Lazartigues E., Zhao B., Chen Y. Neuronal over-expression of ACE2 protects brain from ischemia-induced damage. Neuropharmacology 2014, 79:550-558.
8. Chen Y., Won S.J., Xu Y., Swanson R.A. Targeting microglial activation in stroke therapy: pharmacological tools and gender effects 2014, 21:2146-2155.
9. De Araujo Furtado M., Rossettl F., Chanda S., Yourick D. Exposure to nerve agents: from status epilepticus to neuroinflammation, brain damage, neurogenesis and epilepsy. Neurotoxicology 2012, 33:1476-1490.
10. De Bundel D., Smolders I., Vanderheyden P., Michotte Y. Ang II and Ang IV: unraveling the mechanism of action on synaptic plasticity, memory, and epilepsy. CNS Neurosci. Ther. 2008, 14:315-339.
11. Finnie J.W. Neuroinflammation: beneficial and detrimental effects after traumatic brain injury. Inflammopharmacology 2013, 21:309-320.
12. Füchtbauer L., Groth-Rasmussen M., Holm T.H., Løbner M., Toft-Hansen H., Khorooshi R., Owens T. Angiotensin II Type 1 receptor (AT1) signaling in astrocytes regulates synaptic degeneration-induced leukocyte entry to the central nervous system. Brain Behav. Immun. 2011, 25:897-904.
13. Galanopoulou A.S. Basic mechanisms of catastrophic epilepsy overview from animal models. Brain Dev. 2013, 35:748-756.
14. Hattiangady B., Shetty A.K. Implications of decreased hippocampal neurogenesis in chronic temporal lobe epilepsy. Epilepsia 2008, 5:26-41.
15. Hoshida T. Surgery for temporal lobe epilepsy: historical review and postoperative results. Brain Nerve 2011, 63:313-320.
16. Jang Y.J., Kim J., Shim J., Kim C.Y., Jang J.H., Lee K.W., Lee H.J. Decaffeinated coffee prevents scopolamine-induced memory impairment in rats. Behav. Brain Res. 2013, 15:113-119.
17. Jung K.H., Chu K., Lee S.T., Kim J.Y., Sinn D.I., Kim J.M., Park D.K., Lee J.J., Kim S.U., Kim M., Lee S.K., Roha J.K. Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Neurobiol. Dis. 2006, 23:237-246.
18. Lanz T.V., Ding Z., Ho P.P., Luo J., Agrawal A.N., Srinagesh H., Axtell R., Zhang H., Platten M., Wyss-Coray T., Steinman L. Angiotensin II sustains brain inflammation in mice via TGF-beta. J. Clin. Invest. 2010, 120:2782-2794.
19. Leung L., Cahill C.M. TNF-alpha and neuropathic pain-a review. J. Neuroinflammation 2010, 7:27.
20. Liu H., Roy M., Tian F.F. MicroRNA-based therapy: a new dimension in epilepsy treatment. Int. J. Neurosci. 2013, 123:617-622.
21. Łukawski K., Janowska A., Jakubus T., Tochman-Gawda A., Czuczwar S.J. Angiotensin AT1 receptor antagonists enhance the anticonvulsant action of valproate in the mouse model of maximal electroshock. Eur. J. Pharmacol. 2010, 640:172-177.
22. McKinley M.J., Albiston A.L., Allen A.M., Mathai M.L., May C.N., McAllen R.M., Oldfield B.J., Mendelsohn F.A., Chai S.Y. The brain renin-angiotensin system: location and physiological roles. Int. J. Biochem. Cell Biol. 2003, 35:901-918.
23. Michels M., Vieira A.S., Vuolo F., Zapelini H.G., Mendonça B., Mina F., Dominguini D., Steckert A., Schuck P.F., Quevedo J., Petronilho F., Dal-Pizzol F. The role of microglia activation in the development of sepsis-induced long-term cognitive impairment. Brain Behav. Immun. 2014, 14:S0889-S1591.
24. Mogi M., Horiuchi M. Effect of angiotensin II type 2 receptor on stroke, cognitive impairment and neurodegenerative diseases. Geriatr. Gerontol. Int. 2013, 13:13-18.
25. Otte W.M., Bielefeld P., Dijkhuizen R.M., Braun K.P. Focal neocortical epilepsy affects hippocampal volume, shape, and structural integrity: a longitudinal MRI and immunohistochemistry study in a rat model. Epilepsia 2012, 53(7):1264-1273.
26. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1997, Academic Press, San Diego. 3rd edition.
27. Pereira M.G., Becari C., Oliveira J.A., Salgado M.C., Garcia-Cairasco N., Costa-Neto C.M. Inhibition of the renin-angiotensin system prevents seizures in a rat model of epilepsy. Clin. Sci. (Lond.) 2010, 119:477-482.
28. Racine R.J. Modification of seizure activity by electrical stimulation: IIR motor seizure. Electroencephalogr. Clin. Neurophysiol. 1972, 32:281-294.
29. Rodriguez-Pallares J., Rey P., Parga J.A., Muñoz A., Guerra M.J., Labandeira-Garcia J.L. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol. Dis. 2008, 31:58-73.
30. Ryu S., Shin J.S., Cho Y.W., Kim H.K., Paik S.H., Lee J.H., Chi Y.H., Kim J.H., Kim J.H., Lee K.T. Fimasartan, anti-hypertension drug, suppressed inducible nitric oxide synthase expressions via nuclear factor-kappa B and activator protein-1 inactivation. Biol. Pharm. Bull. 2013, 36:467-474.
31. Saavedra J.M. Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders. Clin. Sci. (Lond.) 2012, 123:567-590.
32. Saavedra J.M., Sánchez-Lemus E., Benicky J. Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications. Psychoneuroendocrinology 2011, 36:1-18.
33. Schneider P., Weber-Fahr W., Schweinfurth N., Ho Y.J., Sartorius A., Spanagel R., Pawlak C.R. Central metabolite changes and activation of microglia after peripheral interleukin-2 challenge. Brain Behav. Immun. 2012, 26(2):277-283.
34. Schwarz J.M., Smith S.H., Bilbo S.D. FACS analysis of neuronal-glial interactions in the nucleus accumbens following morphine administration. Psychopharmacology (Berl) 2013, 230:525-535.
35. Sharma B., Singh N. Experimental hypertension induced vascular dementia: pharmacological, biochemical and behavioral recuperation by angiotensin receptor blocker and acetylcholinesterase inhibitor. Pharmacol. Biochem. Behav. 2012, 102:101-108.
36. Sierra A., Beccari S., Diaz-Aparicio I., Encinas J.M., Comeau S., Tremblay M.E. Surveillance, phagocytosis, and inflammation: how never-resting microglia influence adult hippocampal neurogenesis. Neural. Plast. 2014, 10.1155/2014/610343.
37. Silva J., Pastorello M., Arzola J., Zavala L.E., De Jesús S., Varela M., Matos M.G., de Rosario Garrido M., Israe A. AT1 receptor and NAD(P)H oxidase mediate angiotensin II-stimulated antioxidant enzymes and mitogen-activated protein kinase activity in the rat hypothalamus. J. Renin Angiotensin Aldosterone Syst. 2010, 11:234-242.
38. Sommer W.H., Saavedra J.M. Targeting brain angiotensin and corticotrophin-releasing hormone systems interaction for the treatment of mood and alcohol use disorders. J. Mol. Med. 2008, 86:723-728.
39. Sun H., Huang Y., Yu X., Li Y., Yang J., Li R., Deng Y., Zhao G. Peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, suppresses CD40 expression and attenuates inflammatory responses after lithium pilocarpine-induced status epilepticus in rats. Int. J. Dev. Neurosci. 2008, 26:505-515.
40. Sun H., Yu X., Wu H.Q., Zhang G.L., Zhang R., Zhan S.Q., Wang H.Q., Yao L., Du Y. The PPARγ agonist rosiglitazone prevents cognitive impairment by inhibiting astrocyte activation and oxidative stress following pilocarpine-induced status epilepticus. Neurol. Sci. 2012, 33:559-566.
41. Sun H., Yu X., Wu H.Q., Zhang G.L., Zhang R., Zhan S.Q., Wang H.Q., Yao L., Bu N., Li Y.N. The PPARγ agonist rosiglitazone prevents neuronal loss and attenuates development of spontaneous recurrent seizures through BDNF/TrkB signaling following pilocarpine-induced status epilepticus. Neurochem. Int. 2013, 63:405-412.
42. Tchekalarova J., Georgiev V. Angiotensin peptides modulatory system: how is it implicated in the control of seizure susceptibility?. Life Sci. 2005, 76:955-970.
43. Tchekalarova J., Georgiev V. Ang II and Ang III modulate PTZ seizure threshold in non-stressed and stressed mice: possible involvement of noradrenergic mechanism. Neuropeptides 2006, 40:339-348.
44. Vijayaraghavan L., Natarajan S., Krishnamoorthy E.S. Peri-ictal and ictal cognitive dysfunction in epilepsy. Behav. Neurol. 2011, 24:27-34.
45. 1-receptor blocker and PPAR-γ agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice. Neuropsychopharmacology 2012, 37:2817-2829.
46. Wright J.W., Harding J.W. The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases. Pflugers Arch. 2013, 465:133-151.
47. Wu C.Y., Zha H., Xia Q.Q., Yuan Y., Liang X.Y., Li J.H., Guo Z.Y., Li J.J. Expression of angiotensin II and its receptors in activated microglia in experimentally induced cerebral ischemia in the adult rats. Mol. Cell. Biochem. 2013, 382:47-58.
48. Xanthos D.N., Sandkühler J. Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. Nat. Rev. Neurosci. 2014, 15:43-53.
49. Yananli H.R., Terzioglu B., Goren M.Z., Aker R.G., Aypak C., Onat F.Y. Extracellular hypothalamic γ-aminobutyric acid (GABA) and l-glutamic acid concentrations in response to bicuculline in a genetic absence epilepsy rat model. J. Pharmacol. Sci. 2008, 106:301-309.